BioCentury | Jul 17, 2020
Product Development

Vaccine developments in China include IND acceptance for Fosun, Phase II start for Chongqing Zhifei

...part by NF-kB and marked by increased TNFα and IL-6 signaling. Moleculin in manufacturing deal Moleculin Biotech Inc....
...Inc. Assistance Publique - Hopitaux de Paris Institut National de la Sante et de la Recherche Medicale (INSERM) Moleculin Biotech Inc. Chongqing...
BioCentury | Apr 9, 2020
Product Development

April 8 COVID-19 roundup: National Academy of Sciences says COVID-19 could continue through summer; plus HHS, SAb-CSL, Vanda-UIC, Avacta-Cytiva and more

...diagnosing infection in minutes using a respiratory sample such as saliva. Frankfurt study sparks Moleculin Moleculin Biotech Inc....
...Health and Human Services SAB Biotherapeutics Inc. CSL Ltd. Vanda Pharmaceuticals Inc. University of Illinois at Chicago Avacta Group plc GE Healthcare Moleculin Biotech Inc. Goethe...
BioCentury | Aug 20, 2019
Clinical News

Aug. 20 Clinical Quick Takes: Oxurion misses in Phase II macular edema study; plus NuCana and Moleculin

...is a modified version of gemcitabine. Moleculin will test STAT3 inhibitor in pediatric brain cancer Moleculin Biotech Inc....
...Vascular endothelial growth factor A Mary Romeo, Assistant Editor and Paul Bonanos, Associate Editor Acelarin (MTL-007, NUC-1031) THR-317 WP1066 Moleculin Biotech Inc. Oxurion...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:ICCC) 3/28/19 $9.0 $39.7 $46.9 18% Blueprint Medicines Corp. (NASDAQ:BPMC) 3/28/19 $345.0 $3,608.4 $4,608.4 28% Moleculin Biotech Inc....
BioCentury | Nov 9, 2017
Finance

The return of big

...JV Navire Pharma Inc., which is developing targeted therapies in cancer; the other was with Moleculin Biotech Inc....
...Society, Munich, Germany Merck KGaA (Xetra:MRK), Darmstadt, Germany Mitsubishi UFJ Capital Co. Ltd., Tokyo, Japan Moleculin Biotech Inc....
...Lilly and Co. Indiana University Johnson & Johnson Lead Discovery Center GmbH Max Planck Society Merck KGaA Mitsubishi UFJ Capital Co. Ltd. Moleculin Biotech Inc. National...
BioCentury | Apr 7, 2017
Finance

Taking notice

...2/14/17 $11.5 $68.1 $75.7 11% BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX) 2/10/17 $20.1 $299.3 $382.4 28% Moleculin Biotech Inc....
BioCentury | Feb 10, 2017
Financial News

Moleculin completes follow-on

...On Feb. 9, cancer company Moleculin Biotech Inc. (NASDAQ:MBRX) raised $5 million through the sale of 3.7 million...
...Each whole series A and C warrant is exercisable at $1.50. Moleculin Biotech Inc. (NASDAQ:MBRX), Houston, Texas Alicia Parker Moleculin Biotech Inc....
BioCentury | Jul 11, 2016
Finance

Ground up

...6/21/16 $70.0 $250.6 $250.4 0% Mereo BioPharma Group Ltd. (LSE:MPH) 6/6/16 $16.4 $205.2 $260.1 27% Moleculin Biotech Inc....
BioCentury | Jun 6, 2016
Financial News

Moleculin Biotech completes IPO

Moleculin Biotech Inc. (NASDAQ:MBRX), Houston, Texas Business: Cancer Date completed: 2016-06-02 Type: IPO Raised: $9.2 million Shares: 1.5 million Price: $6 Shares after offering: 13.8 million Underwriters: Bonwick Capital Partners; Network 1 Financial Securities WIR...
BioCentury | May 9, 2016
Financial News

Moleculin Biotech amends IPO

Moleculin Biotech Inc. , Houston, Texas Business: Cancer Date announced: 2016-05-02 Type: IPO To be raised: Up to $12 million Shares: 2 million Price: $6 Underwriters: Bonwick Capital Partners; Network 1 Financial Securities Note: Moleculin amended...
Items per page:
1 - 10 of 12
BioCentury | Jul 17, 2020
Product Development

Vaccine developments in China include IND acceptance for Fosun, Phase II start for Chongqing Zhifei

...part by NF-kB and marked by increased TNFα and IL-6 signaling. Moleculin in manufacturing deal Moleculin Biotech Inc....
...Inc. Assistance Publique - Hopitaux de Paris Institut National de la Sante et de la Recherche Medicale (INSERM) Moleculin Biotech Inc. Chongqing...
BioCentury | Apr 9, 2020
Product Development

April 8 COVID-19 roundup: National Academy of Sciences says COVID-19 could continue through summer; plus HHS, SAb-CSL, Vanda-UIC, Avacta-Cytiva and more

...diagnosing infection in minutes using a respiratory sample such as saliva. Frankfurt study sparks Moleculin Moleculin Biotech Inc....
...Health and Human Services SAB Biotherapeutics Inc. CSL Ltd. Vanda Pharmaceuticals Inc. University of Illinois at Chicago Avacta Group plc GE Healthcare Moleculin Biotech Inc. Goethe...
BioCentury | Aug 20, 2019
Clinical News

Aug. 20 Clinical Quick Takes: Oxurion misses in Phase II macular edema study; plus NuCana and Moleculin

...is a modified version of gemcitabine. Moleculin will test STAT3 inhibitor in pediatric brain cancer Moleculin Biotech Inc....
...Vascular endothelial growth factor A Mary Romeo, Assistant Editor and Paul Bonanos, Associate Editor Acelarin (MTL-007, NUC-1031) THR-317 WP1066 Moleculin Biotech Inc. Oxurion...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:ICCC) 3/28/19 $9.0 $39.7 $46.9 18% Blueprint Medicines Corp. (NASDAQ:BPMC) 3/28/19 $345.0 $3,608.4 $4,608.4 28% Moleculin Biotech Inc....
BioCentury | Nov 9, 2017
Finance

The return of big

...JV Navire Pharma Inc., which is developing targeted therapies in cancer; the other was with Moleculin Biotech Inc....
...Society, Munich, Germany Merck KGaA (Xetra:MRK), Darmstadt, Germany Mitsubishi UFJ Capital Co. Ltd., Tokyo, Japan Moleculin Biotech Inc....
...Lilly and Co. Indiana University Johnson & Johnson Lead Discovery Center GmbH Max Planck Society Merck KGaA Mitsubishi UFJ Capital Co. Ltd. Moleculin Biotech Inc. National...
BioCentury | Apr 7, 2017
Finance

Taking notice

...2/14/17 $11.5 $68.1 $75.7 11% BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX) 2/10/17 $20.1 $299.3 $382.4 28% Moleculin Biotech Inc....
BioCentury | Feb 10, 2017
Financial News

Moleculin completes follow-on

...On Feb. 9, cancer company Moleculin Biotech Inc. (NASDAQ:MBRX) raised $5 million through the sale of 3.7 million...
...Each whole series A and C warrant is exercisable at $1.50. Moleculin Biotech Inc. (NASDAQ:MBRX), Houston, Texas Alicia Parker Moleculin Biotech Inc....
BioCentury | Jul 11, 2016
Finance

Ground up

...6/21/16 $70.0 $250.6 $250.4 0% Mereo BioPharma Group Ltd. (LSE:MPH) 6/6/16 $16.4 $205.2 $260.1 27% Moleculin Biotech Inc....
BioCentury | Jun 6, 2016
Financial News

Moleculin Biotech completes IPO

Moleculin Biotech Inc. (NASDAQ:MBRX), Houston, Texas Business: Cancer Date completed: 2016-06-02 Type: IPO Raised: $9.2 million Shares: 1.5 million Price: $6 Shares after offering: 13.8 million Underwriters: Bonwick Capital Partners; Network 1 Financial Securities WIR...
BioCentury | May 9, 2016
Financial News

Moleculin Biotech amends IPO

Moleculin Biotech Inc. , Houston, Texas Business: Cancer Date announced: 2016-05-02 Type: IPO To be raised: Up to $12 million Shares: 2 million Price: $6 Underwriters: Bonwick Capital Partners; Network 1 Financial Securities Note: Moleculin amended...
Items per page:
1 - 10 of 12